New FDA guidance documents.
Bradshaw
Sheldon T
ST
Office of Chief Counsel, the Food and Drug Administration, USA.
D018712:Analgesics, Non-Narcotic; D018926:Anti-Allergic Agents; D000962:Antimalarials; D003257:Consumer Product Safety; D017277:Drug Approval; D004348:Drug Labeling; D004878:Ergotamine; D006140:Guaifenesin; D017408:Guidelines as Topic; D006801:Humans; D011725:Pyridines; D011803:Quinine; D014481:United States; D014486:United States Food and Drug Administration
D018712:Analgesics, Non-Narcotic; D018926:Anti-Allergic Agents; D000962:Antimalarials; D011725:Pyridines; D006140:Guaifenesin; D011803:Quinine; D004878:Ergotamine